Keros Therapeutics, Inc. — Director's Dealing 2021

Apr 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Keros Therapeutics, Inc. (KROS)
CIK: 0001664710
Period of Report: 2021-04-12

Reporting Person: Lachey Jennifer (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-12	Common Stock	M	5300	$0.30	Acquired	76487	Direct
2021-04-12	Common Stock	S	998	$59.10	Disposed	75489	Direct
2021-04-12	Common Stock	S	3473	$59.99	Disposed	72016	Direct
2021-04-12	Common Stock	S	729	$61.08	Disposed	71287	Direct
2021-04-12	Common Stock	S	100	$61.72	Disposed	71187	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-12	Employee Stock Option (right to buy)	$0.30	M	5300	Disposed	2028-03-25	Common Stock (5300)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.54 to $59.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5).

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.55 to $60.43 inclusive.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.58 to $61.535 inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.625 to $61.725 inclusive

F6: Immediately exercisable.